JUNO DIAGNOSTICS™ ANNOUNCES ADDITIONAL COVERAGE OF JUNO HAZEL™ NIPS TEST BY COMMERCIAL NETWORKS WELLMARK, AMERICA'S CHOICE PROVIDER NETWORK, AND ALIVIO HEALTH

THIS CONTINUES THE RAPID UPTAKE OF COVERED LIVES, BOTH COMMERCIALLY AND THROUGH MEDICAID, FOR JUNO HAZEL™, AN INNOVATIVE SOLUTION TO INCREASE ACCESSIBILITY AND AFFORDABILITY OF NON-INVASIVE PRENATAL SCREENING (NIPS)

SAN DIEGO, June 14, 2023 /PRNewswire/ -- Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today shared that there has been strong reception to Juno Hazel™, a non-invasive prenatal screening (NIPS) solution by the insurance community. The Company's novel NIPS approach offers a convenient and affordable avenue to access prenatal care for providers and patients, including those located remotely or within medical deserts. The Juno Hazel™ tests provide a promising solution to ensure all parents-to-be and families have an equal opportunity to access high-quality prenatal information on their own time and terms.

"The initial response from payors for Juno Hazel™ has been overwhelmingly positive.  This underscores the company's vision around affordability and accessibility for NIPS," said Dirk van den Boom, Founder and Chief Executive Officer of JunoDx™. "We have always intended to work closely with payors to ensure all pregnant women have access to an elevated standard of care. This early validation confirms the need for a better option for testing that puts the needs of patients and providers first."

To date, there are currently over 29 million covered lives that have access to Juno Hazel™ as an in-network service. Covered individuals include a diverse range of commercial and Medicaid payors who see the benefits of offering an accessible and affordable option for NIPS testing..

About Juno Diagnostics™

Juno Diagnostics™ is a category-defining health company bringing vital prenatal health information to patients by combining accessibility, affordability, and transparency. The Company has developed a proprietary Sample Collection Kit and Device to facilitate capillary blood-based testing. Its lead product, the Juno Hazel™ test, is a non-invasive prenatal screening (NIPS) test that utilizes the proprietary Sample Collection Kit and improves access to high-quality testing results without the high cost, long lead times, and phlebotomy requirements of traditional NIPS.

For more information, visit www.junodx.com and engage with us on LinkedIn.

Investor and Media Contact:
Amy Conrad
Juniper Point
[email protected]
858-366-3243

SOURCE JunoDx